Matches in Wikidata for { <http://www.wikidata.org/entity/Q97046893> ?p ?o ?g. }
Showing items 1 to 48 of
48
with 100 items per page.
- Q97046893 description "clinical trial" @default.
- Q97046893 description "ensayo clínico" @default.
- Q97046893 description "ensayu clínicu" @default.
- Q97046893 description "klinisch onderzoek" @default.
- Q97046893 description "клінічне випробування" @default.
- Q97046893 description "կլինիկական փորձարկում" @default.
- Q97046893 description "临床试验" @default.
- Q97046893 name "Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension" @default.
- Q97046893 name "Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension" @default.
- Q97046893 type Item @default.
- Q97046893 label "Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension" @default.
- Q97046893 label "Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension" @default.
- Q97046893 prefLabel "Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension" @default.
- Q97046893 prefLabel "Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension" @default.
- Q97046893 P1050 Q97046893-0729524D-2BBF-4E99-96C2-F79BA28BFCAC @default.
- Q97046893 P1050 Q97046893-91FB37EB-84E2-472D-B411-836D79ACCDDF @default.
- Q97046893 P1050 Q97046893-A6DC4177-714A-458F-9380-BF7050361FA7 @default.
- Q97046893 P1132 Q97046893-859BB2DD-9677-441E-8DA8-A291B84F7126 @default.
- Q97046893 P1476 Q97046893-6AEA5145-CA2A-4669-A9DB-D9A90781F950 @default.
- Q97046893 P17 Q97046893-E6ACAEE4-A940-41D5-B7A7-DCEC943A933B @default.
- Q97046893 P1813 Q97046893-C507B367-DCAB-4C69-B813-51590175A9D7 @default.
- Q97046893 P2899 Q97046893-F0C0D468-27BC-42D3-AE18-DE3B6582D28D @default.
- Q97046893 P3098 Q97046893-309358D9-0D09-441B-A261-479E2068FA0D @default.
- Q97046893 P31 Q97046893-C0A15099-27E9-4FE8-B209-255404FBDAD7 @default.
- Q97046893 P4135 Q97046893-AC8ACED6-CF61-4F56-996C-00E460340F93 @default.
- Q97046893 P4844 Q97046893-F1174777-6C25-46AA-85AB-76CD9D2E56DD @default.
- Q97046893 P580 Q97046893-D9500985-DDA7-400B-8177-CAC898D39D15 @default.
- Q97046893 P582 Q97046893-75BAD320-1DBA-4CB2-96B3-22037EDE6748 @default.
- Q97046893 P6099 Q97046893-B9C78CD2-D13E-4CC7-9E8D-A3538AB07918 @default.
- Q97046893 P8005 Q97046893-C1866491-B9B7-4FB7-966B-CB25DAB27AD8 @default.
- Q97046893 P8363 Q97046893-10B58B2A-4C8F-4234-9AB4-6C4C59BC5972 @default.
- Q97046893 P1050 Q159701 @default.
- Q97046893 P1050 Q9294051 @default.
- Q97046893 P1050 Q95566669 @default.
- Q97046893 P1132 "+670" @default.
- Q97046893 P1476 "Phase 3, Randomized, Adaptive Dose-Selection, Multi-regional, Double-Masked, Parallel-Group, 3-Month Trial Evaluating the Safety and Efficacy of NCX 470 vs. Latanoprost 0.005% in Subjects With Open-Angle Glaucoma or Ocular Hypertension (Mont Blanc)" @default.
- Q97046893 P17 Q30 @default.
- Q97046893 P1813 "Mont Blanc" @default.
- Q97046893 P2899 "+18" @default.
- Q97046893 P3098 "NCT04445519" @default.
- Q97046893 P31 Q30612 @default.
- Q97046893 P4135 "+84" @default.
- Q97046893 P4844 Q634959 @default.
- Q97046893 P580 "2020-06-01T00:00:00Z" @default.
- Q97046893 P582 "2021-12-01T00:00:00Z" @default.
- Q97046893 P6099 Q42824827 @default.
- Q97046893 P8005 Q76649708 @default.
- Q97046893 P8363 Q78089383 @default.